Amanda H Ceravolo1, Janie J Yang2, Alicia Latham3, Arnold J Markowitz2, Jinru Shia4, Joe Mermelstein5, Delia Calo2, Hans Gerdes2, Emmy Ludwig2, Mark A Schattner2, Zsofia K Stadler3,6, Elizabeth Kantor7, Mengmeng Du7, Robin B Mendelsohn2. 1. Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Amandacer1212@gmail.com. 2. Gastroenterology, Hepatology and Nutrition Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Division of Gastroenterology, Department of Medicine, Cooper University Health Care, Camden, NJ, USA. 6. Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 7. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
BACKGROUND AND AIMS: Lynch syndrome (LS) is the most common cause of hereditary colorectal cancer and is associated with an increased lifetime risk of gastric and duodenal cancers of 8-16% and 7%, respectively; therefore, we aim to describe an esophagogastroduodenoscopy (EGD) surveillance program for upper gastrointestinal (GI) precursor lesions and cancer in LS patients. METHODS: Patients who either had positive genetic testing or met clinical criteria for LS who had a surveillance EGD at our institution from 1996 to 2017 were identified. Patients were included if they had at least two EGDs or an upper GI cancer detected on the first surveillance EGD. EGD and pathology reports were extracted manually. RESULTS: Our cohort included 247 patients with a mean age of 47.1 years (SD 12.6) at first EGD. Patients had a mean of 3.5 EGDs (range 1-16). Mean duration of follow-up was 5.7 years. Average interval between EGDs was 2.3 years. Surveillance EGD detected precursor lesions in 8 (3.2%) patients, two (0.8%) gastric cancers and two (0.8%) duodenal cancers. Two interval cancers were diagnosed: a duodenal adenocarcinoma was detected 2 years, 8 months after prior EGD and a jejunal adenocarcinoma was detected 1 year, 9 months after prior EGD. CONCLUSIONS: Our data suggest that surveillance EGD is a useful tool to help detect precancerous and cancerous upper GI lesions in LS patients. To our knowledge, this is the first study to examine a program of surveillance EGDs in LS patients. More data are needed to determine the appropriate surveillance interval.
BACKGROUND AND AIMS: Lynch syndrome (LS) is the most common cause of hereditary colorectal cancer and is associated with an increased lifetime risk of gastric and duodenal cancers of 8-16% and 7%, respectively; therefore, we aim to describe an esophagogastroduodenoscopy (EGD) surveillance program for upper gastrointestinal (GI) precursor lesions and cancer in LS patients. METHODS: Patients who either had positive genetic testing or met clinical criteria for LS who had a surveillance EGD at our institution from 1996 to 2017 were identified. Patients were included if they had at least two EGDs or an upper GI cancer detected on the first surveillance EGD. EGD and pathology reports were extracted manually. RESULTS: Our cohort included 247 patients with a mean age of 47.1 years (SD 12.6) at first EGD. Patients had a mean of 3.5 EGDs (range 1-16). Mean duration of follow-up was 5.7 years. Average interval between EGDs was 2.3 years. Surveillance EGD detected precursor lesions in 8 (3.2%) patients, two (0.8%) gastric cancers and two (0.8%) duodenal cancers. Two interval cancers were diagnosed: a duodenal adenocarcinoma was detected 2 years, 8 months after prior EGD and a jejunal adenocarcinoma was detected 1 year, 9 months after prior EGD. CONCLUSIONS: Our data suggest that surveillance EGD is a useful tool to help detect precancerous and cancerous upper GI lesions in LS patients. To our knowledge, this is the first study to examine a program of surveillance EGDs in LS patients. More data are needed to determine the appropriate surveillance interval.
Authors: Polymnia Galiatsatos; Christopher Labos; Marie Jeanjean; Kyle Miller; William D Foulkes Journal: Turk J Gastroenterol Date: 2017-10-25 Impact factor: 1.852
Authors: M Aarnio; R Sankila; E Pukkala; R Salovaara; L A Aaltonen; A de la Chapelle; P Peltomäki; J P Mecklin; H J Järvinen Journal: Int J Cancer Date: 1999-04-12 Impact factor: 7.396
Authors: Francis M Giardiello; John I Allen; Jennifer E Axilbund; C Richard Boland; Carol A Burke; Randall W Burt; James M Church; Jason A Dominitz; David A Johnson; Tonya Kaltenbach; Theodore R Levin; David A Lieberman; Douglas J Robertson; Sapna Syngal; Douglas K Rex Journal: Gastroenterology Date: 2014-08 Impact factor: 22.682
Authors: Elena M Stoffel; Pamela B Mangu; Stephen B Gruber; Stanley R Hamilton; Matthew F Kalady; Michelle Wan Yee Lau; Karen H Lu; Nancy Roach; Paul J Limburg Journal: J Clin Oncol Date: 2014-12-01 Impact factor: 44.544
Authors: Lisette G Capelle; Nicole C T Van Grieken; Hester F Lingsma; Ewout W Steyerberg; Willem J Klokman; Marco J Bruno; Hans F A Vasen; Ernst J Kuipers Journal: Gastroenterology Date: 2009-11-10 Impact factor: 22.682
Authors: Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava Journal: J Natl Cancer Inst Date: 2004-02-18 Impact factor: 13.506
Authors: L Renkonen-Sinisalo; P Sipponen; M Aarnio; R Julkunen; L A Aaltonen; S Sarna; H J Järvinen; J P Mecklin Journal: Scand J Gastroenterol Date: 2002-05 Impact factor: 2.423
Authors: H F A Vasen; G Möslein; A Alonso; I Bernstein; L Bertario; I Blanco; J Burn; G Capella; C Engel; I Frayling; W Friedl; F J Hes; S Hodgson; J-P Mecklin; P Møller; F Nagengast; Y Parc; L Renkonen-Sinisalo; J R Sampson; A Stormorken; J Wijnen Journal: J Med Genet Date: 2007-02-27 Impact factor: 6.318
Authors: Hans F A Vasen; Ignacio Blanco; Katja Aktan-Collan; Jessica P Gopie; Angel Alonso; Stefan Aretz; Inge Bernstein; Lucio Bertario; John Burn; Gabriel Capella; Chrystelle Colas; Christoph Engel; Ian M Frayling; Maurizio Genuardi; Karl Heinimann; Frederik J Hes; Shirley V Hodgson; John A Karagiannis; Fiona Lalloo; Annika Lindblom; Jukka-Pekka Mecklin; Pal Møller; Torben Myrhoj; Fokko M Nagengast; Yann Parc; Maurizio Ponz de Leon; Laura Renkonen-Sinisalo; Julian R Sampson; Astrid Stormorken; Rolf H Sijmons; Sabine Tejpar; Huw J W Thomas; Nils Rahner; Juul T Wijnen; Heikki Juhani Järvinen; Gabriela Möslein Journal: Gut Date: 2013-02-13 Impact factor: 23.059